1 |
van Rhee F, Voorhees P, Dispenzieri A, Fossa A, Srkalovic G, Ide M, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 2018;132:2115-24.
|
2 |
Kamisawa T, Funata N, Hayashi Y, Eishi Y, Koike M, Tsuruta K, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 2003;38:982-4.
DOI
|
3 |
Yamashita K, Haga H, Kobashi Y, Miyagawa-Hayashino A, Yoshizawa A, Manabe T. Lung involvement in IgG4-related lymphoplasmacytic vasculitis and interstitial fibrosis: report of 3 cases and review of the literature. Am J Surg Pathol 2008;32:1620-6.
DOI
|
4 |
Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, et al. Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol 2016;3:e163-75.
DOI
|
5 |
van Rhee F, Greenway A, Stone K. Treatment of idiopathic Castleman disease. Hematol Oncol Clin North Am 2018;32:89-106.
DOI
|
6 |
van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, et al. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget 2015;6:30408-19.
DOI
|
7 |
Fajgenbaum DC, Shilling D. Castleman disease pathogenesis. Hematol Oncol Clin North Am 2018;32:11-21.
DOI
|
8 |
Wallace ZS, Naden RP, Chari S, Choi H, Della-Torre E, Dicaire JF, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol 2020;72:7-19.
DOI
|
9 |
Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD, Burt ME, et al. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer 1999;85:706-17.
DOI
|
10 |
Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M, et al. The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol 2018;180:206-16.
DOI
|
11 |
Palestro G, Turrini F, Pagano M, Chiusa L. Castleman's disease. Adv Clin Path 1999;3:11-22.
|
12 |
Vassallo R, Ryu JH, Colby TV, Hartman T, Limper AH. Pulmonary Langerhans'-cell histiocytosis. N Engl J Med 2000;342:1969-78.
DOI
|
13 |
Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 2017;129:1646-57.
DOI
|
14 |
Shahidi H, Myers JL, Kvale PA. Castleman's disease. Mayo Clin Proc 1995;70:969-77.
DOI
|
15 |
Inoue D, Zen Y, Abo H, Gabata T, Demachi H, Kobayashi T, et al. Immunoglobulin G4-related lung disease: CT findings with pathologic correlations. Radiology 2009;251:260-70.
DOI
|
16 |
Mochizuki H, Kato M, Higuchi T, Koyamada R, Arai S, Okada S, et al. Overlap of IgG4-related disease and multicentric Castleman's disease in a patient with skin lesions. Intern Med 2017;56:1095-9.
DOI
|
17 |
Sato Y, Kojima M, Takata K, Morito T, Asaoku H, Takeuchi T, et al. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease. Mod Pathol 2009;22:589-99.
DOI
|
18 |
Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956;9:822-30.
DOI
|
19 |
Takenaka K, Takada K, Kobayashi D, Moriguchi M, Harigai M, Miyasaka N. A case of IgG4-related disease with features of Mikulicz's disease, and retroperitoneal fibrosis and lymphadenopathy mimicking Castleman's disease. Mod Rheumatol 2011;21:410-4.
DOI
|
20 |
Huang H, Feng R, Li J, Song X, Li S, Xu K, et al. Castleman disease-associated diffuse parenchymal lung disease: A STROBEcompliant retrospective observational analysis of 22 cases in a tertiary Chinese hospital. Medicine (Baltimore)2017;96:e8173.
DOI
|